ecrin-mdr-crcClinical2020IPD Sharing (as of November 2020): NoGastrointestinal NeoplasmsColorectal cancerGastrointestinal CancerTumor vaccine therapyGastric cancerPatients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer.Esophageal cancerGastrointestinal NeoplasmsTumor Vaccine TherapyGastric CancerGastrointestinal CancerColorectal CancerEsophageal CancerPatients With Histologically Confirmed Diagnosis Of Colorectal Carcinoma (left-sided Or Rectal), Esophageal Carcinoma, Or Gastric Cancer.Interventionalhttps://newmdr.ecrin.org/Study/2324408Germany11Anti-PD-1TMV-018FlucytosineOncolytic virus5-FCECRIN MDRWithdrawnfalseA Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal TractThis study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.2020-11-152324408NCT041953732019-003550-88